JU
₹946.00
+2.10(+0.22%)
JUBLPHARMA₹946.00+0.22%
Group Companies
Foreign Flows
sector level — not this stockHealthcare sector+₹2,114 Crnet foreign buying
2026-09-01 to 2026-09-15This is the flow into the whole Healthcare sector, not into JUBLPHARMA. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.
Supply Chain
suppliers and customers in the graphMacro Sensitivity
rates, currency, commoditiesRevenue by Segment
Business Group
Geographic Exposure
revenue, imports, currencyScenario analysis
stated assumptions, shown workingsJUBLPHARMA exposure summary
In its latest segment disclosure (Jun 2026), Radiopharma was the largest segment at 45.0% of segment revenue, followed by Contract Development and Manufacturing Organisation - Sterile Injectables at 22.9%. Jubilant Pharmova Limited is a constituent of 3 indices, with its largest weights in S&P BSE 500 (0.04%). It is part of the Jubilant Bhartia business group. 10 exchange-traded funds hold the stock.
| Index memberships | 3 |
|---|---|
| ETFs holding | 10 |
| Largest segment | Radiopharma · 45.0% |
| Business group | Jubilant Bhartia |